A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

The first report to compare what pharmaceutical companies are doing to bring antimicrobial resistance under control. By highlighting innovative actions, it encourages more companies to seize opportunities for change.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • Novartis drops antibiotic development program
Media - published on 12 Jul 2018

Novartis drops antibiotic development program

Chris Dall of the Center for Infectious Disease Research and Policy (CIDRAP) quotes Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, on Novartis’ recent announcement to drop its antibacterial and antiviral research programs.

“Novartis leaving innovation in antibiotics is unfortunate, as we still need effective replacement antibiotics, and Novartis has a few in development. They are in discussions to divest them, so hopefully there’s a suitable partner to complete their development.” – Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.